# Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

> **NCT03452540** · PHASE2 · TERMINATED · sponsor: **Afimmune** · enrollment: 9 (actual)

## Conditions studied

- Severe Acute Decompensated Alcoholic Hepatitis

## Interventions

- **DRUG:** 1000mg DS102 (BID)

## Key facts

- **NCT ID:** NCT03452540
- **Lead sponsor:** Afimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-28
- **Primary completion:** 2019-06-19
- **Final completion:** 2020-03-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452540, "Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03452540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*